UAEM WESTERN
  • About Us
  • Join Us
  • Events
  • News
  • More

Ebola Crisis a Result of Industry Greed

11/14/2014

0 Comments

 
Picture
The Ebola virus disease (EVD) was first identified in 1976. “Then why are we still without a vaccine for this deadly disease?” you may ask.

Almost a decade ago, scientists in Canada and the Unites States reported the creation of an Ebola vaccine for monkeys that guaranteed resistance. The results were reported in a reputable journal, and there was a lot of buzz in the health community. Testing in humans was expected to start within two years, and a product ready by 2010 or 2011.  However, the endeavor was shelved. 

Why? Until recently, Ebola was a rare disease that infected only a few hundred people at a time in underdeveloped regions of Africa. There was insufficient market incentive for pharmaceutical companies in developed countries to invest resources into developing a vaccine and making it available. Bringing a new vaccine to market typically costs $1 billion to $1.5 billion, so there was no potential for profit. 

Unfortunately, it has taken 5,000 deaths and the threat of a global spread to convince pharmaceutical companies otherwise. Sadly, many more people will die until a solution can be reached.  

The only way to prevent this tragedy in the future is for governments to provide incentives for research into neglected diseases.


Written by: Alex Pearson 
Alex is a second year Neuroscience student at Western University. He is currently the co-Director of Empowerment at UAEM Western. 

0 Comments

    Archives

    February 2021
    December 2020
    February 2019
    March 2018
    February 2018
    December 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2015
    January 2015
    November 2014

    Categories

    All

    RSS Feed

Powered by Create your own unique website with customizable templates.
  • About Us
  • Join Us
  • Events
  • News
  • More